Currently, there are 28.24M common shares owned by the public and among those 24.01M shares have been available to trade.
The company’s stock has a 5-day price change of -2.52% and 3.59% over the past three months. KRYS shares are trading 39.45% year to date (YTD), with the 12-month market performance up to 42.46% higher. It has a 12-month low price of $93.95 and touched a high of $191.78 over the same period. KRYS has an average intraday trading volume of 297.96K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 2.93%, 4.71%, and 27.48% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Krystal Biotech Inc (NASDAQ: KRYS) shares accounts for 85.91% of the company’s 28.24M shares outstanding.
It has a market capitalization of $4.94B and a beta (3y monthly) value of 0.83. The stock’s trailing 12-month PE ratio is 91.90, while the earnings-per-share (ttm) stands at $1.88. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.48% over the week and 3.92% over the month.
Earnings per share for the fiscal year are expected to increase by 579.10%, and 113.06% over the next financial year.
Looking at the support for the KRYS, a number of firms have released research notes about the stock. Goldman stated their Buy rating for the stock in a research note on November 20, 2023, with the firm’s price target at $160. Cantor Fitzgerald coverage for the Krystal Biotech Inc (KRYS) stock in a research note released on October 24, 2023 offered a Overweight rating with a price target of $100. Citigroup was of a view on October 12, 2023 that the stock is Buy, while Berenberg gave the stock Buy rating on September 07, 2023, issuing a price target of $154. Stifel on their part issued Buy rating on April 18, 2023.
